Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 6/20 | 0.34 |
| ▸ | CA2 | P00918 | 6/20 | 0.34 |
| ▸ | CA7 | P43166 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 6/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3329784 | 1.00 | TDP1 (0.42) | TDP1MEN1KMT2ATSHRAPLNR | |
| SCHEMBL28583327 | 1.00 | TDP1 (0.42) | TDP1MEN1KMT2ATSHRAPLNR | |
| SCHEMBL5494091 | 0.93 | APLNR (0.40) | TDP1MEN1KMT2AAPLNRCA1 | |
| SCHEMBL3709339 | 0.89 | TDP1 (0.47) | TDP1MEN1KMT2AAPLNRCA1 | |
| Hydrochloric Acid SCHEMBL6521555 | 0.87 | TDP1 (0.46) | TDP1MEN1KMT2AAPLNRCA1 | |
| SCHEMBL25143061 | 0.86 | APLNR (0.36) | TDP1MEN1KMT2AAPLNRCA1 | |
| SCHEMBL17301885 | 0.86 | APLNR (0.36) | TDP1MEN1KMT2AAPLNRCA1 | |
| SCHEMBL20151957 | 0.86 | APLNR (0.36) | TDP1MEN1KMT2AAPLNRCA1 | |
| SCHEMBL17337904 | 0.86 | APLNR (0.36) | TDP1MEN1KMT2AAPLNRCA1 | |
| SCHEMBL22515382 | 0.86 | CA2 (0.36) | TDP1MEN1KMT2AAPLNRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191263-A1 | Valency platform molecules comprising aminooxy groups | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-08-16 | — | — | US | disclosed |
| EP-1092027-B1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 BETA 2 GP1 POLYPEPTIDES AND METHODS OF USING SAME | JOLLA PHARMA (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060141597-A1 | A conjugate of biologically active molecules e.g peptides, proteins, nucleic acids, hormones, lipids, antibodies, saccharides, epitopes, enzymes, drugs etc. and a polyoxyethylene containing aminoxy groups | JONES DAVID S | 2006-06-29 | — | — | US | disclosed |
| US-6858210-B1 | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same | LA JOLLA PHARMACEUTICAL CO. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20050004351-A1 | Therapeutic and diagnostic domain 1 beta2GP1 polypeptides and methods of using same | MARQUIS DAVID M (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040224366-A1 | Valency platform molecules comprising aminooxy groups | JONES DAVID S (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1183230-A1 | VALENCY PLATFORM MOLECULES COMPRISING AMINOOXY GROUPS | LA JOLLA PHARMACEUTICAL (US) | 2002-03-06 | — | — | EP | disclosed |
| EP-1092027-A1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 BETA 2 GP1 POLYPEPTIDES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL COMPANY (CA) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000075105-A1 | VALENCY PLATFORM MOLECULES COMPRISING AMINOOXY GROUPS | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999064595-A1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191263-A1 | Valency platform molecules comprising aminooxy groups | DAO, PAM, BCAT2 | TDP1 3756/4885MEN1 3498/4885KMT2A 457/4885 |
| US-20060141597-A1 | A conjugate of biologically active molecules e.g peptides, proteins, nucleic acids, hormones, lipids, antibodies, saccharides, epitopes, enzymes, drugs etc. and a polyoxyethylene containing aminoxy groups | SHBG, DAO, DNPEP | TDP1 3051/4885MEN1 2706/4885KMT2A 480/4885 |
| US-20040224366-A1 | Valency platform molecules comprising aminooxy groups | DAO, PAM, BCAT2 | TDP1 3756/4885MEN1 3498/4885KMT2A 457/4885 |
| US-20050004351-A1 | Therapeutic and diagnostic domain 1 beta2GP1 polypeptides and methods of using same | PLTP, PA2G4, PAG1 | TDP1 384/4885MEN1 1505/4885KMT2A 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.